根治性治疗III期非小细胞肺癌患者认知功能障碍的危险因素:NVALT-11研究的次要发现
基于III期NVALT-11试验(观察 vs 预防性颅脑照射)的次要分析,采用EORTC-QLQ-C30在7个预设时间点评估认知功能。无PCI组84例中43例(51.2%)至少一次报告认知障碍,认知障碍呈动态变化分四型。基线认知功能评分<75是后续认知障碍最重要的危险因素,效应量大。
要点
- 无PCI组43/84(51.2%)至少一次报告认知障碍,其中持续性31.4%、可逆性25.7%、复发性28.6%、交替性14.3%。
- 基线认知功能评分<75是后续认知障碍的显著危险因素,效应量大(全部患者β=-23.47,p<0.001)。
- 年轻(≤60岁)、鳞状组织学类型和PCI为无临床相关性的危险因素(β>-10,p<0.05)。
核心结论
- 认知障碍随时间呈动态变化,可分为持续性、可逆性、复发性和交替性四种类型。
- 基线认知障碍(评分<75)是III期非小细胞肺癌患者后续认知障碍最重要的危险因素。
研究设计与样本
- III期NVALT-11试验的次要分析,比较观察与预防性颅脑照射(PCI)在根治性放化疗±手术治疗的III期非小细胞肺癌患者中的作用。
- 采用EORTC-QLQ-C30在7个预设时间点评估认知功能,以评分<75定义为认知障碍,采用广义估计方程(GEE)在多重插补前后进行分析。
- 平均差异<10分、10-<20分、≥20分分别视为无、中等和大的临床效应。
主要发现
- 无PCI组43/84(51.2%)至少一次报告认知障碍,其中持续性31.4%、可逆性25.7%、复发性28.6%、交替性14.3%,PCI组结果相似。
- 两臂基线认知功能相当,基线评分<75是后续认知障碍的显著危险因素且效应量大(无PCI组β=-23.30,p<0.001;PCI组β=-22.34,p<0.001;全部患者β=-23.47,p<0.001)。
- 年轻(≤60岁)、鳞状组织学类型和PCI为无临床相关性的危险因素(β>-10,p<0.05)。
- 认知功能随时间下降(β=-0.26,p=0.001),但基线已有认知障碍的患者除外(β=0.141,p=0.33)。
关键数值与推荐
- 认知障碍定义为EORTC-QLQ-C30评分<75。
- 平均差异<10分为无临床效应,10-<20分为中等临床效应,≥20分为大临床效应。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: To identify risk factors for self-reported cognitive impairment in radically treated stage III non-small cell lung cancer (NSCLC). METHODS: Cognitive functioning was assessed using the EORTC-QLQ-C30 at seven pre-specified time points in the phase III NVALT-11 trial (observation versus prophylactic cranial irradiation [PCI] in stage III NSCLC treated with chemo-radiotherapy ± surgery). Cognition was analyzed as binary (impairment or not) and continuous outcome, respectively, using generalized estimating equation (GEE) before and after multiple imputation. A score < 75 was defined as cognitive impairment. A mean difference by < 10, 10-<20, ≥ 20 points was regarded as of no, moderate, and large clinical effect, respectively. We categorized the cognitive impairment into four types based on changes over time: sustained, reversible, recurring, and alternating. RESULTS: In the no-PCI arm, 43/84 [51.2%] reported cognitive impairment at least once, of which 31.4% were sustained, 25.7% reversible, 28.6% recurring, and 14.3% alternating. Results were similar in the PCI arm. Cognitive functioning at baseline was comparable in two arms and a score < 75 was a significant risk factor with large effect for subsequent cognitive impairment (no-PCI: β = -23.30, p < 0.001; PCI arm: β = -22.34, p < 0.001; All: β = -23.47, p < 0.001). Younger age (≤60y), squamous histology, and PCI were risk factors without clinical relevance (β > -10, p < 0.05). Cognitive functioning declined over time (β = -0.26, p = 0.001) except for patients with cognitive impairment at baseline (β = 0.141, p = 0.33). CONCLUSION: Cognitive impairment is dynamic over time with four types. Baseline cognitive impairment (score < 75) is the most important risk factor for subsequent cognitive impairment in stage III NSCLC. Note: This work has been partly reported as an oral presentation at the ESTRO 2021 meeting (OC-0176).
引用
- Zeng H, Hendriks LEL, Witlox WJA, et al. Risk factors for cognitive impairment in radically treated stage III NSCLC: Secondary findings of the NVALT-11 study. Radiother Oncol. 2023. PMID: 36934893. doi:10.1016/j.radonc.2023.109627
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。